Point72 Asset Management L.P. bought a new stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 289,739 shares of the company’s stock, valued at approximately $6,916,000. Point72 Asset Management L.P. owned 0.48% of Caribou Biosciences at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in the stock. Farallon Capital Management LLC acquired a new position in Caribou Biosciences during the third quarter worth $70,738,000. BlackRock Inc. acquired a new position in Caribou Biosciences during the third quarter worth $28,204,000. FIL Ltd acquired a new position in Caribou Biosciences during the third quarter worth $20,544,000. Coatue Management LLC acquired a new position in Caribou Biosciences during the third quarter worth $16,709,000. Finally, 72 Investment Holdings LLC acquired a new position in Caribou Biosciences during the third quarter worth $11,316,000. 56.13% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:CRBU opened at $10.00 on Friday. Caribou Biosciences, Inc. has a 52-week low of $9.34 and a 52-week high of $32.65. The stock’s fifty day simple moving average is $12.80 and its 200-day simple moving average is $19.41.
In related news, VP Ryan Fischesser acquired 7,387 shares of Caribou Biosciences stock in a transaction dated Tuesday, January 11th. The shares were acquired at an average cost of $4.00 per share, for a total transaction of $29,548.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders bought 14,650 shares of company stock worth $49,085 over the last 90 days.
A number of research analysts recently weighed in on the company. Citigroup raised Caribou Biosciences from a “neutral” rating to a “buy” rating and set a $27.00 price objective on the stock in a report on Friday, November 12th. Oppenheimer initiated coverage on Caribou Biosciences in a research report on Tuesday, November 30th. They set an “outperform” rating and a $36.00 target price on the stock. HC Wainwright initiated coverage on Caribou Biosciences in a research report on Tuesday, November 30th. They set a “buy” rating and a $28.00 target price on the stock. Brookline Capital Management reiterated a “buy” rating on shares of Caribou Biosciences in a research report on Monday, February 14th. Finally, Brookline Capital Acquisition initiated coverage on Caribou Biosciences in a research report on Monday, February 14th. They set a “buy” rating and a $19.00 target price on the stock. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Caribou Biosciences has a consensus rating of “Buy” and an average price target of $27.71.
About Caribou Biosciences
Caribou Biosciences Inc is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc is based in BERKELEY, Calif.
Featured Stories
Want More Great Investing Ideas?